Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 14, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $78.54 to $2,171,047.50.

Highlighted Stocks Traded by Insiders:

Freescale Semiconductor (FSL) - FREE Research Report

Elson Jeffrey R, who is SVP, HR and Security at Freescale Semiconductor, sold 2,714 shares at $26.42 on Jan. 14, 2015. Following this transaction, the SVP, HR and Security owned 59,973 shares meaning that the stake was reduced by 4.33% with the 2,714-share transaction.

Wuamett Jennifer, who is SVP, GC and Secretary at Freescale Semiconductor, sold 992 shares at $26.42 on Jan. 14, 2015. Following this transaction, the SVP, GC and Secretary owned 36,510 shares meaning that the stake was reduced by 2.65% with the 992-share transaction.

The shares most recently traded at $25.59, down $0.83, or 3.25% since the insider transaction. Historical insider transactions for Freescale Semiconductor go as follows:

  • 4-Week # shares sold: 2,529
  • 12-Week # shares sold: 31,737
  • 24-Week # shares sold: 39,404

The average volume for Freescale Semiconductor has been 2.5 million shares per day over the past 30 days. Freescale Semiconductor has a market cap of $7.8 billion and is part of the technology sector and electronics industry. Shares are up 1.82% year-to-date as of the close of trading on Wednesday.

Freescale Semiconductor, Ltd. provides embedded processing solutions for automotive, networking, industrial, and consumer markets worldwide. The company has a P/E ratio of 160.6. Currently, there are 6 analysts who rate Freescale Semiconductor a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FSL - FREE

TheStreet Quant Ratings

rates Freescale Semiconductor as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, good cash flow from operations, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Freescale Semiconductor Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 1,500 shares at $18.35 on Jan. 14, 2015. Following this transaction, the President owned 115,075 shares meaning that the stake was reduced by 1.29% with the 1,500-share transaction.

The shares most recently traded at $18.50, up $0.15, or 0.81% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 23,232
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 51,240

The average volume for NxStage Medical has been 465,300 shares per day over the past 30 days. NxStage Medical has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 2.96% year-to-date as of the close of trading on Wednesday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Stag Industrial (STAG) - FREE Research Report

Butcher Benjamin S, who is Chairman, CEO and President at Stag Industrial, sold 1,614 shares at $26.10 on Jan. 14, 2015. Following this transaction, the Chairman, CEO and President owned 83,596 shares meaning that the stake was reduced by 1.89% with the 1,614-share transaction.

The shares most recently traded at $26.17, up $0.07, or 0.28% since the insider transaction. Historical insider transactions for Stag Industrial go as follows:

  • 4-Week # shares bought: 2,544
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 2,544
  • 12-Week # shares sold: 10,760
  • 24-Week # shares bought: 2,544
  • 24-Week # shares sold: 21,767

The average volume for Stag Industrial has been 429,600 shares per day over the past 30 days. Stag Industrial has a market cap of $1.7 billion and is part of the financial sector and real estate industry. Shares are up 8.37% year-to-date as of the close of trading on Wednesday.

STAG Industrial, Inc. is a real estate investment trust. The firm invests in the real estate markets of United States. It is engaged in investment and management of real estate assets. STAG Industrial, Inc. was founded on July 21, 2010 and is based in Boston, Massachusetts. The stock currently has a dividend yield of 5.15%. Currently, there are 6 analysts who rate Stag Industrial a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STAG - FREE

TheStreet Quant Ratings

rates Stag Industrial as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and poor profit margins. Get the full

Stag Industrial Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null